Genentech

Biotech pioneer, now part of Roche. Represented by Aviv Regev at Session II.

Strategy: Lab in the Loop

Four iterative loops spanning targets, indications, medicines, and patients:

• Cross-screen foundation models with Recursion
• Multimodal patient atlases
• AI delivered 50× better hit rate vs. medicinal chemist on same data
• De novo antibody design, virtual screening, and immunogenicity cleanup are routine

Key Drugs Mentioned

• Inavolisib (PI3Kα), giredestrant (oral SERD), divarasib (KRAS G12C), fenebrutinib (CNS-penetrant BTK)
• Autogene cevumeran — personalized neoantigen vaccine with BioNTech

Historical

• Co-developed anti-VEGF therapy for retinal disease with Anthony Adamis (ranibizumab/Lucentis)
• Susvimo — implantable ranibizumab reservoir